Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma

References

• Connell LC, Harding JJ, Shia J, et al. Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Chin Clin Oncol. 2016;5(5):66. doi:10.21037/cco.2016.10.02
   Google Scholar
• Beaufrere A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol. 2021;74(5):1212–1224. doi:10.1016/j.jhep.2021.01.035
   PubMedGoogle Scholar
• Brunt E, Aishima S, Clavien PA, et al. cHCC‐CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology. 2018;68(1):113–126. doi:10.1002/hep.29789
   PubMed Web of Science ®Google Scholar
• Shetty AS, Fowler KJ, Brunt EM, et al. Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging. 2014;39(2):310–322. doi:10.1007/s00261-013-0069-6
   Google Scholar
• Santillan C, Chernyak V, Sirlin C. Li-rads categories: concepts, definitions, and criteria. Abdom Radiol. 2018;43(1):101–110. doi:10.1007/s00261-017-1334-x
   Web of Science ®Google Scholar
• Mitchell DG, Bruix J, Sherman M, et al. Li-rads (liver imaging reporting and data system): summary, discussion, and consensus of the li-rads management working group and future directions. Hepatology. 2015;61(3):1056–1065. doi:10.1002/hep.27304
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee SS, Park SH, et al. Li-rads classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology. 2019;290(2):388–397. doi:10.1148/radiol.2018181290
   PubMed Web of Science ®Google Scholar
• Jeon SK, Joo I, Lee DH, et al. Combined hepatocellular cholangiocarcinoma: li-rads v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2019;29(1):373–382. doi:10.1007/s00330-018-5605-x
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68:723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Gigante E, Ronot M, Bertin C, et al. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma. Liver Int. 2019;39(12):2386–2396. doi:10.1111/liv.14261
   PubMed Web of Science ®Google Scholar
• Lee HS, Kim MJ, An C. How to utilize lr-m features of the li-rads to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol. 2019;29(5):2408–2416. doi:10.1007/s00330-018-5893-1
   Web of Science ®Google Scholar
• Zhou Y, Yin S, Zhao L, et al. CEUS and CT/MRI LI-RADS in association with serum biomarkers for differentiation of combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma. Front Onco. 2022;12:897090. doi:10.3389/fonc.2022.897090
   Web of Science ®Google Scholar
• Jiang H, Song B, Qin Y, et al. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol. 2021;31(6):3638–3648. doi:10.1007/s00330-020-07488-z
   PubMed Web of Science ®Google Scholar
• Shin J, Lee S, Hwang JA, et al. MRI-diagnosis of category LR-M observations in the liver imaging reporting and data system v2018: a systematic review and meta-analysis. Eur Radiol. 2022;32(5):3319–3326. doi:10.1007/s00330-021-08382-y
   Web of Science ®Google Scholar
• Rhee H, An C, Kim HY, et al. Hepatocellular carcinoma with irregular rim-like arterial phase hyperenhancement: more aggressive pathologic features. Liver Cancer. 2019;8(1):24–40. doi:10.1159/000488540
   PubMed Web of Science ®Google Scholar
• Cha H, Choi JY, Park YN, et al. Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI. Eur Radiol. 2022;24. doi:10.1007/s00330-022-09105-7
   Google Scholar
• Banerjee S, Wang DS, Kim HJ, et al. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology. 2015;62(3):792–800. doi:10.1002/hep.27877
   PubMed Web of Science ®Google Scholar
• An C, Kim DW, Park Y-N, et al. Single hepatocellular carcinoma: preoperative MR imaging to predict early recurrence after curative resection. Radiology. 2015;276(2):433–443. doi:10.1148/radiol.15142394
   PubMed Web of Science ®Google Scholar
• Sempoux C, Kakar S, Kondo F, et al. Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours: Digestive System Tumours, 5th ed. Lyon: IARC; 2019:260–262.
   Google Scholar
• Chernyak V, Fowler KJ, Kamaya A, et al. Sirlin, liver imaging reporting and data system (LI- RADS) version 2018: imaging of Hepatocellular Carcinoma In At-Risk Patients. Radiology. 2018;289:816–830. doi:10.1148/radiol.2018181494
   PubMed Web of Science ®Google Scholar
• Sammon J, Fischer S, Menezes R, et al. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma. Cancer Imaging. 2018;18(1):8. doi:10.1186/s40644-018-0142-z
   PubMedGoogle Scholar
• Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109–121. doi:10.1016/j.jhep.2020.08.013
   PubMed Web of Science ®Google Scholar
• Rhee H, Kim MJ, Park YN, et al. Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria. J Magn Reson Imaging. 2012;35(2):393–398. doi:10.1002/jmri.22828
   PubMed Web of Science ®Google Scholar
• Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology. 2011;261(3):834–844. doi:10.1148/radiol.11101840
   PubMed Web of Science ®Google Scholar
• Choi SH, Jeon SK, Lee SS, et al. Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 who classification and impact on li-rads classification at liver MRI. Eur Radiol. 2021;31(12):9479–9488. doi:10.1007/s00330-021-07984-w
   Web of Science ®Google Scholar
• Li R, Yang D, Tang CL, et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer. 2016;16:158. doi:10.1186/s12885-016-2156-x
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745–761. doi:10.1053/j.gastro.2016.11.048
   PubMed Web of Science ®Google Scholar
• Tanimizu N, Nakamura Y, Ichinohe N, et al. Hepatic biliary epithelial cells acquire epithelial integrity but lose plasticity to differentiate into hepatocytes in vitro during development. J Cell Sci. 2013;126(Pt22):5239–5246. doi:10.1242/jcs.133082
   Google Scholar
• Chen Y, Wong PP, Sjeklocha L, et al. Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture. Hepatology. 2012;55(2):563–574. doi:10.1002/hep.24712
   PubMed Web of Science ®Google Scholar